Taken just once a week, strawberry flavored BINOSTO offers an easy-to-take option for patients seeking to decrease their risks of suffering a disabling fracture.
BINOSTO, a product of Mission Pharmacal and the first and only buffered solution of alendronate for the treatment of osteoporosis, was approved in 2012 by the U.
BINOSTO represents a true innovation in the delivery of osteoporosis and bone fracture prevention medication, especially for those patients who prefer not to swallow tablets, suffer with dysphagia, or have other medical difficulties swallowing pills.
We are very pleased to add BINOSTO to our line of bone health products," says Terry Herring, President of Commercial Operations at Mission Pharmacal.
Utilizing EffRx's formulation technology, BINOSTO is the first and only buffered effervescent therapeutic to deliver the gold standard in osteoporosis treatment and fracture prevention of alendronate sodium in an easy-to-swallow, buffered solution.
EffRx CEO Christer Rosen adds, "We believe Mission is the logical choice for bringing BINOSTO to the U.
We are stepping into a new business phase and it is very encouraging to get the news from Mission about the positive reaction BINOSTO
has received from the healthcare community in the United States.
We are very excited about our partnership with EffRx and look forward to helping deliver BINOSTO
to women with osteoporosis who have difficulty with pills or shots and to men who also struggle with this disease.
Important Safety Information BINOSTO
is contraindicated in patients with the following conditions:
is formulated with the same 70 mg of alendronate sodium as other standard alendronate weekly therapies, yet it is delivered in a tablet that dissolves in water.
October 2012 brought a new treatment option when BINOSTO
(TM)(alendronate sodium) Effervescent Tablet became available in the United States by prescription.